ArticleInternational journal of molecular sciences2026
Serum Metabolomics Reveals Carnitine Metabolism as a Possible Central Metabolic Axis of Pemafibrate Action.
Chufang Qian, Xuguang Zhang, Zhe Zhang, Kazuhiro Tanabe, Chihiro Hayashi, Hiroki Kittaka, Qianqian Zheng, Jiali Chen, Sakura Yuki, Xiyue Yang and 6 more
Abstract read
In one paragraphArticle in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Chufang QianDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.
Xuguang ZhangDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.
Zhe ZhangDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.
Kazuhiro TanabeMedical Solution Promotion Department, Medical Solution Segment, LSI Medience Corporation, Tokyo 174-8555, Japan.ORCID 0000-0003-2671-1217 Chihiro HayashiMedical Solution Promotion Department, Medical Solution Segment, LSI Medience Corporation, Tokyo 174-8555, Japan.ORCID 0009-0002-1548-2383 Hiroki KittakaKyushu Professional Search Limited Liability Partnership, Fukuoka 819-0388, Japan.
Qianqian ZhengDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.ORCID 0009-0009-0999-3751 Jiali ChenDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.ORCID 0009-0005-9982-9947 Sakura YukiDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.
Xiyue YangDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.
Yifan DiaoDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.
Takero NakajimaDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.ORCID 0000-0002-2678-788X Takanobu IwadareDepartment of Gastroenterology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.ORCID 0000-0003-0430-6819 Takefumi KimuraDepartment of Gastroenterology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.ORCID 0000-0002-1481-1029 Makoto NakamutaDepartment of Gastroenterology, Kyushu Medical Center, Fukuoka 810-8563, Japan.
Naoki TanakaDepartment of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.ORCID 0000-0002-3212-3836 Funding
Japan Agency for Medical Research and Development JP23fk0210125, JP256f0137007, and JP26fk0210190Shinshu Public Utility Foundation for Promotion of Medical Sciences 2024
6 · The paper itselfAbstract
Pemafibrate (PEM), a novel selective peroxisome proliferator-activated receptor α modulator, is widely used to treat dyslipidemia, yet its systemic metabolic effects remain incompletely defined. We performed untargeted serum metabolomics in patients with hypertriglyceridemia at baseline and at 2 and 8 weeks after PEM treatment. PEM increased cystine, L-methionine, uridine, and L-carnitine, while decreasing lipid-related metabolites, including lysophosphatidylcholines, adenosine, and erucic acid (22:1). Circulating carnitine levels rose progressively, with a significant elevation at 8 weeks, whereas ketone bodies showed only modest, non-significant increases. Consistently, increases in circulating and tissue carnitine were also observed in male 8-week-old C57BL/6J mice treated with a clinically relevant dose of PEM for 2 weeks. Mechanistically, PEM did not significantly alter genes involved in carnitine biosynthesis or transport, but upregulated hepatic carnitine O-acetyltransferase and carnitine O-octanoyltransferase, key enzymes of carnitine utilization and turnover. Collectively, these findings suggest that enhanced carnitine metabolism represents an important metabolic axis of PEM action.
Indexed as
ButyratesCarnitineMetabolomeMetabolomicsOxazolesAnimalsBenzoxazolesFemaleHumansLiverMaleMiceMice, Inbred C57BLPPAR alphaBenzoxazolesButyratesCarnitineOxazolesPPAR alpha(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidcarnitinecarnitine o-acetyltransferasecarnitine O-octanoyltransferasemetabolomicspemafibrateselective peroxisome proliferator-activated receptor α modulator
Identifiers
PMID42511595
PMCPMC13411396
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390